TY - JOUR AU - Claes, Jomme AU - Cornelissen, v尼克AU - McDermott, Clare AU - Moyna, Niall AU - Pattyn, Nele AU - Cornelis, Nils AU - Gallagher, Anne AU - McCormack, Ciara AU - Newton, Helen AU - Gillain, Alexandra AU - Budts, Werner AU - Goetschalckx, Kaatje AU - Woods, Catherine AU - Moran, Kieran AU - Buys, Roselien PY - 2020 DA - 2020/2/4 TI -可行性，可接受性，技术支持的心脏康复平台(身体活动促进健康)的临床有效性:随机对照试验JO - J Med Internet Res SP - e14221 VL - 22 IS - 2kw -心脏康复KW -身体活动KW -技术KW - eHealth AB -背景:心脏康复(CR)作为心血管疾病(cvd)的二级预防非常有效。CR的摄取仍然不理想(30%的符合条件的患者)，长期坚持积极运动的生活方式的比例更低。需要创新的战略来抵消这一现象。目的:开发身体活动促进健康(PATHway)系统，为心血管疾病患者提供全面、远程监控、基于家庭的CR计划。PATHway- 1研究旨在探讨其在III期CR期间的可行性和临床疗效。方法:采用单盲、多中心、随机对照的先导试验，参与者按1:1的比例随机分为PATHway (PW)干预组或常规护理(UC)对照组。在完成II期CR和6个月随访时评估结果。主要终点是身体活动(PA;活动图GT9X链接)。次要结局包括身体健康、可改变的心血管危险因素、内皮功能、颈总动脉内膜-中膜厚度和生活质量。 System usability and patients’ experiences were evaluated only in PW. A mixed-model analysis of variance with Bonferroni adjustment was used to analyze between-group effects over time. Missing values were handled by means of an intention-to-treat analysis. Statistical significance was set at a 2-sided alpha level of .05. Data are reported as mean (SD). Results: A convenience sample of 120 CVD patients (mean 61.4 years, SD 13.5 years; 22 women) was included. The PATHway system was deployed in the homes of 60 participants. System use decreased over time and system usability was average with a score of 65.7 (SD 19.7; range 5-100). Moderate-to-vigorous intensity PA increased in PW (PW: 127 [SD 58] min to 141 [SD 69] min, UC: 146 [SD 66] min to 143 [SD 71] min; Pinteraction=.04; effect size of 0.42), while diastolic blood pressure (PW: 79 [SD 11] mmHg to 79 [SD 10] mmHg, UC: 78 [SD 9] mmHg to 83 [SD 10] mmHg; Pinteraction=.004; effect size of −0.49) and cardiovascular risk score (PW: 15.9% [SD 10.4%] to 15.5% [SD 10.5%], UC: 14.5 [SD 9.7%] to 15.7% [SD 10.9%]; Pinteraction=.004; effect size of −0.36) remained constant, but deteriorated in UC. Conclusions: This pilot study demonstrated the feasibility and acceptability of a technology-enabled, remotely monitored, home-based CR program. Although clinical effectiveness was demonstrated, several challenges were identified that could influence the adoption of PATHway. Trial Registration: ClinicalTrials.gov NCT02717806; https://clinicaltrials.gov/ct2/show/NCT02717806 International Registered Report Identifier (IRRID): RR2-10.1136/bmjopen-2017-016781 SN - 1438-8871 UR - //www.mybigtv.com/2020/2/e14221 UR - https://doi.org/10.2196/14221 UR - http://www.ncbi.nlm.nih.gov/pubmed/32014842 DO - 10.2196/14221 ID - info:doi/10.2196/14221 ER -